Is NAD+ legal in Australia? This is a common question for those interested in advancing wellness options under Australian law. The short answer is that NAD+ is not a banned substance, but it is also not an ARTG-approved medicine. That means its legal status centres on how it can be accessed, under what conditions, and who is permitted to supply or prescribe it. Understanding the regulations matters because the same question, is NAD+ legal in Australia, gets very different answers depending on who is selling something. This article gives a clear summary using TGA-published sources and explains exactly what is permitted by law.
The short answer: NAD+ is not illegal, but it is not TGA-approved either
NAD+ is not included on the Australian Register of Therapeutic Goods (ARTG), and it is not a prohibited or banned substance in Australia. This means that possessing or inquiring about NAD+ is not unlawful, but supplying, importing, or exporting NAD+ as a medicine requires regulatory pathways. NAD+ cannot be marketed as a listed (AUST L) medicine or supplied as an over-the-counter supplement. This distinction is crucial: NAD+ sits in a regulatory grey area where lawfulness depends on the method of access, as outlined by the TGA. The regulatory position on NAD+ in Australia remains subject to strict TGA oversight.
What "not on the ARTG" actually means
Registered, listed and unapproved goods explained
Every medicine supplied, imported, or exported in Australia must be entered on the ARTG, unless exempted or otherwise authorised by the TGA. Registered medicines have been fully evaluated, listed medicines conform to permitted ingredients and claims, and goods not included are known as "unapproved goods". Unapproved goods are not evaluated by the TGA for quality, safety, or effectiveness.
Why NAD, NAD+ and NADH are not permitted in listed medicines
The TGA safety alert, NAD, NAD+, NADH or NMN medicines sold in Australia, states that NAD, NAD+ and NADH are not currently permitted ingredients in AUST L medicines. Their inclusion in products' names or branding is also prohibited if it could imply actual content. If goods refer to these compounds but lack an AUST L, AUST L(A), or AUST R number, they may be considered unapproved goods or even illegally supplied.
Where NMN sits after the December 2025 determination
As of 10 December 2025, NMN was added to the Therapeutic Goods (Permissible Ingredients) Determination (No. 4) 2025, but only for oral use. NMN in listed medicines must be for adults only, at a maximum of 500 mg per day, and for up to 12 weeks. These strict conditions mean that, while NMN is permitted in some settings, it has a very different regulatory profile to NAD+ and NADH. This is a regulatory fact only, not usage guidance for any individual.
What the TGA has actually said about NAD+ products
The safety alert on NAD, NAD+, NADH and NMN products
The TGA’s safety alert outlines how NAD, NAD+, and NADH are not permitted in listed medicines. Marketing or supplying products containing or referring to these ingredients, where not ARTG-listed, risks their status as unapproved or potentially illegally supplied goods. Consumers are urged to check regulatory credentials before accessing such products.
The August 2026 guidance on product names and advertising
TGA guidance published on 12 August 2026 declared that using NAD, NAD+, NADH or NMN in the name of a listed medicine is unacceptable where it could imply presence of those compounds. Product names and marketing must comply with these updated standards. This guidance is to ensure that product promotion does not mislead consumers about content or legality. For an overview of legitimate access pathways, see our complete guide to NAD+ therapy in Australia.
Retail supplements versus a prescribed preparation: two different categories
Retail supplements referencing NAD+ are not approved medicines in Australia and may not meet TGA standards. In contrast, a prescribed preparation refers to NAD+ prescribed following individual clinical assessment and in compliance with Australian regulations. This distinction separates lawful prescription from retail or direct-to-consumer sales. For details on risks of grey-market options, review the difference between GP-prescribed peptides and grey-market suppliers.
The lawful access pathway in Australia
Individual prescription from a registered Australian practitioner
For substances not on the ARTG, such as NAD+, the lawful pathway involves individual prescription by a registered Australian practitioner and dispensing by a licensed Australian compounding pharmacy, never by retail or direct supply. Clinics or telehealth providers may facilitate a proper assessment with a practitioner, but access is only lawful when strictly following all regulatory requirements. A medical assessment does not guarantee access to any specific therapy. Prescriptions will only be issued when clinically appropriate, as determined by a registered Australian practitioner. Any compounded NAD+ is only prescribed following individual clinical assessment and in compliance with Australian regulations.
Dispensing through a licensed Australian compounding pharmacy
Once prescribed, NAD+ preparations (including injectables, which are not ARTG-listed) must be compounded and supplied by a licensed Australian compounding pharmacy. The pharmacy is responsible for dispensing only as directed by a valid prescription, following all legal requirements. Compounded medicines, including NAD+, have not been evaluated by the TGA for quality, safety, or effectiveness. The prescribing and dispensing chain is the regulatory control that applies in the absence of ARTG review. For a pathway summary see how GP-prescribed NAD+ injection therapy is accessed.
Why buying NAD+ online without a prescription is the risky path
NAD+ products purchased online or supplied without an Australian prescription fall outside the TGA-afforded regulatory framework. Goods sold via unapproved or "grey market" suppliers risk being substandard, counterfeit, or illegally imported. Importing or supplying unapproved medicines outside the TGA framework can breach Australian law. No product is considered safe or lawful simply because it is accessible online. See how to get peptides prescribed in Australia for details on the accredited path for therapeutic access.
Where personal importation fits, and its limits
The TGA Personal Importation Scheme allows individuals to import certain medicines for personal use, but with strict limits. The law permits only a three-month supply per import (and fifteen months total over one year), the medicine must not be supplied or sold onward, and if the medicine is prescription-only in Australia, the importer must have a valid Australian prescription. The medicine also cannot contain controlled substances or be counterfeit. More than three months requires an Australian-registered doctor to apply under the Special Access Scheme. Importing unapproved medicines carries significant compliance risks and does not bypass the requirements for clinical assessment and prescription under Australian law.
How a GP-prescribed telehealth assessment works with HPH
Individuals interested in peptide therapies, including the lawful possibility of NAD+, must undergo a comprehensive telehealth assessment with a registered Australian GP. The process involves submitting a detailed medical history, with the GP weighing suitability for any prescribed preparation following individual clinical assessment and in compliance with Australian regulations. Not every assessment results in a prescription, and only those therapies determined clinically appropriate may be considered. This pathway is stringent, with medical decision-making resting solely with the practitioner. For information on GP-prescribed peptide therapy through Australian telehealth, including assessment considerations, see our in-depth explainer.
Frequently asked questions
Is NAD+ legal in Australia?
NAD+ is not a banned substance in Australia, but it is not ARTG-approved either. It may be lawfully accessed only via an individual prescription pathway, after assessment by a registered Australian practitioner, and dispensed by a licensed Australian compounding pharmacy. Without this process, supply is unlawful.
Do I need a prescription for NAD+ in Australia?
Yes, NAD+ may only be lawfully accessed through a prescription from a registered Australian practitioner following individual clinical assessment and in compliance with Australian regulations. This applies to any compounded preparation intended for therapeutic use.
Is NAD+ approved by the TGA?
No, injectable NAD+ is not entered on the ARTG and has not been evaluated by the TGA for quality, safety, or effectiveness. For prescribed use, assessment and compliance with regulations are required.
Are NAD+ supplements the same as a prescribed preparation?
No, supplements referencing NAD+ and prescribed preparations are regulated differently. Only prescribed NAD+ is lawful after clinical GP assessment, and retail products may be unapproved or illegal if supplied without ARTG listing or exemption.
Can I import NAD+ from overseas?
Importation for personal use is subject to strict controls under the TGA Personal Importation Scheme, including a valid Australian prescription and supply limits. Import is not a bypass for Australian prescription or regulatory requirements, and sale or distribution is prohibited.
Assessment is required to determine eligibility for any prescribed therapies. No medicines are supplied without a qualified doctor’s approval under Australian law.
This article provides general information about NAD+ and the Australian regulatory framework. It does not constitute medical or legal advice, and does not promote or advertise any specific product or therapy. Consult a qualified health practitioner for personalised advice. All medicines (including compounded medicines) carry risks and are only supplied following independent medical assessment in compliance with Australian law.